Novel Hepatitis B Virus Capsid-Targeting Antiviral that Aggregates Core Particles and Inhibits Nuclear Entry of Viral Cores

An estimated 240 million are chronically infected with hepatitis B virus (HBV), which can lead to liver disease, cirrhosis, and hepatocellular carcinoma. Currently, HBV treatment options include only nucleoside reverse transcriptase inhibitors and the immunomodulatory agent interferon alpha, and the...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:ACS Infect Dis
Hlavní autoři: Huber, Andrew D., Pineda, Dallas L., Liu, Dandan, Boschert, Kelsey N., Gres, Anna T., Wolf, Jennifer J., Coonrod, Emily M., Tang, Jing, Laughlin, Thomas G., Yang, Qiongying, Puray-Chavez, Maritza N., Ji, Juan, Singh, Kamalendra, Kirby, Karen A., Wang, Zhengqiang, Sarafianos, Stefan G.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2019
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6510658/
https://ncbi.nlm.nih.gov/pubmed/30582687
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsinfecdis.8b00235
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky